AbbVie Inc. (NYSE:ABBV) saw unusually large options trading activity on Monday. Investors purchased 278 put options on the stock. This represents an increase of 121% compared to the average daily volume of 126 put options.

ABBV has been the subject of several analyst reports. Societe Generale upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Vetr upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $74.86 price target for the company in a research report on Thursday, July 6th. Jefferies Group LLC restated a “buy” rating and set a $94.00 price target (up from $92.00) on shares of AbbVie in a research report on Monday, July 17th. BidaskClub lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $85.00 price target on shares of AbbVie in a research report on Thursday, August 3rd. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $89.90.

In related news, insider Henry O. Gosebruch sold 18,000 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $70.09, for a total value of $1,261,620.00. Following the completion of the transaction, the insider now directly owns 96,074 shares in the company, valued at $6,733,826.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Rapp bought 4,000 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was bought at an average price of $70.45 per share, with a total value of $281,800.00. Following the completion of the transaction, the director now directly owns 15,498 shares of the company’s stock, valued at approximately $1,091,834.10. The disclosure for this purchase can be found here. Insiders sold 379,890 shares of company stock valued at $27,187,817 over the last quarter. 0.23% of the stock is owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Accident Compensation Corp lifted its holdings in AbbVie by 24.7% during the 1st quarter. Accident Compensation Corp now owns 66,200 shares of the company’s stock valued at $4,314,000 after buying an additional 13,100 shares in the last quarter. Investec Asset Management LTD lifted its holdings in AbbVie by 3.6% during the 1st quarter. Investec Asset Management LTD now owns 166,978 shares of the company’s stock valued at $10,880,000 after buying an additional 5,801 shares in the last quarter. Comerica Securities Inc. lifted its holdings in AbbVie by 832.7% during the 1st quarter. Comerica Securities Inc. now owns 66,443 shares of the company’s stock valued at $4,329,000 after buying an additional 59,319 shares in the last quarter. Suntrust Banks Inc. lifted its holdings in AbbVie by 3.7% during the 1st quarter. Suntrust Banks Inc. now owns 1,216,484 shares of the company’s stock valued at $79,265,000 after buying an additional 43,617 shares in the last quarter. Finally, Clean Yield Group lifted its holdings in AbbVie by 25.0% during the 1st quarter. Clean Yield Group now owns 9,598 shares of the company’s stock valued at $625,000 after buying an additional 1,920 shares in the last quarter. 68.26% of the stock is owned by hedge funds and other institutional investors.

AbbVie (NYSE ABBV) opened at 89.90 on Thursday. AbbVie has a 52 week low of $55.06 and a 52 week high of $90.95. The stock’s 50 day moving average is $81.10 and its 200 day moving average is $71.64. The company has a market capitalization of $143.31 billion, a P/E ratio of 22.11 and a beta of 1.51.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 28th. The company reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.02. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The firm had revenue of $6.94 billion during the quarter, compared to analysts’ expectations of $6.93 billion. During the same period in the previous year, the company earned $1.26 EPS. The firm’s revenue for the quarter was up 7.6% compared to the same quarter last year. On average, equities research analysts expect that AbbVie will post $5.52 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be paid a dividend of $0.64 per share. The ex-dividend date is Thursday, October 12th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 2.85%. AbbVie’s dividend payout ratio is presently 62.90%.

ILLEGAL ACTIVITY NOTICE: “Investors Purchase High Volume of AbbVie Put Options (ABBV)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/05/investors-purchase-high-volume-of-abbvie-put-options-abbv.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.